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Abstract
Transfusion has been related to poor survival after surgery in several cancers. Recently, timing of transfusion
has been proposed as crucial in the determination of poor survival expectanies after surgery, in fact, intra-
operative but not postoperative transfusion were found to be related. We conﬁrmed these ﬁndings in patients
who underwent radical cystectomy because of bladder cancer; physicians should avoid use of transfusion
intraoperatively.
Background: Previous studies have demonstrated that perioperative blood transfusion (BT) is associated with a
signiﬁcantly increased risk of cancer recurrence and mortality after radical cystectomy (RC). Recently, it was shown for
the ﬁrst time that intraoperative transfusion has a detrimental effect on cancer survival. The aim of the current study
was to validate this ﬁnding in a single European institution. Patients and Methods: The study focused on 1490
consecutive nonmetastatic bladder cancer patients treated with RC at a single tertiary care referral center between
January 1990 and August 2013. KaplaneMeier analyses and Cox regression analyses were used to assess the effect
of timing of BT administration (no transfusion vs. intraoperative transfusion vs. postoperative transfusion vs. intra-
operative and postoperative transfusion) on cancer-speciﬁc mortality (CSM), overall mortality (OM), and disease
recurrence. Results: Mean age at the time of RC was 67 years. Overall, 322 (21.6%) patients received intraoperative
BT and 97 (6.5%) received postoperative BT. At a mean follow-up time of 125 months (median, 110 months), the
5- and 10-year CSM rate was 846 (58%) and 715 (48%), respectively. In multivariable analyses patients who received
intraoperative BT had greater risk of disease recurrence (hazard ratio [HR], 1.24; P < .04), CSM (HR, 1.60; P < .02), and
OM (HR, 1.45; P < .03). Conversely, this effect disappears with postoperative BT (all P > .2). Conclusion: Our study
conﬁrms that intraoperative, but not postoperative BT, are related to a detrimental effect on survival after RC. These
results should be take into account by physicians to administer BT using the correct timing.
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2 - Clistatus.2 In this context, several biochemical or hematological pa-
rameters have been described as possible predictors of survival in
BCa patients treated with RC.3-7 Speciﬁcally, perioperative blood
transfusion (PBT) has been recently proposed by several in-
vestigators as a possible predictor of poor survival expectance after
RC,8-11 that underlying hematological factors have a direct role in
BCa. This effect was known and investigated in several other
malignancies, including breast, larynx, colon-rectal, and prostate
cancer.12-17 Several mechanisms have been proposed to explain
this effect, which include immunosuppressive effects from blood
transfusion (BT),18 a decreased host immunity caused by anes-
thetics and opioids,19 and a release of increased numbers of
circulating tumor cells caused by surgical manipulation.20 None
of the aforementioned studies evaluated the effect of the timing of
BT (intraoperative vs. postoperative) in terms of outcomes after
RC. In this context, Abel et al21 in a multiinstitutional cohort of
360 patients, assessed whether individuals who received BT
during their surgery had better outcomes compared with patients
who received BT during their postoperative hospitalization.
They validated their results in a validation cohort of 1770 pa-
tients, demonstrating that intraoperative transfusion but not
postoperative transfusion was associated with lower survival
expectances.
In the current study we aimed to assess the effect of intraoperative
BT on survival after RC for BCa in a large contemporary European
cohort of patients with nonmetastatic BCa treated at a tertiary
referral center, to test the hypothesis that the intraoperative BT in
our center increased the risk of disease recurrence, cancer-speciﬁc
mortality (CSM), and overall mortality (OM).
Patients and Methods
Study Population
After institutional review board approval was obtained, we eval-
uated 1490 consecutive patients with nonmetastatic BCa treated
with RC and bilateral PLND at a single tertiary care referral center
between January 1990 and August 2013.
Covariates
Preoperative patient characteristics were evaluated at admission
for RC and included: age at time of surgery, sex, body mass index
(BMI), Charlson Comorbidity Index ([CCI] which was set to
0 vs. 1 vs.  2), preoperative hemoglobin (Hb) level, and anemic
status. Tumor characteristics included pathological T stage (pT0-T2
vs. pT3 vs. pT4; classiﬁed according to the 2009 tumor, node,
metastases classiﬁcation22), carcinoma in situ, and surgical margin
status. Perioperative BT was deﬁned as transfusion of allogeneic red
blood cells during RC or in the postoperative hospitalization.
Administration of BT was based on the discretion of the treating
physicians and stratiﬁed according intraoperative or postoperative
administration. Anemic status was deﬁned as a preoperative
Hb value recorded as < 13 g/dL for men and < 12 g/dL for
women, according to the World Health Organization (WHO)
deﬁnition.23
Dedicated genitourinary pathologists examined all surgical spec-
imens. All removed LNs were examined for the presence of nodal
metastases. LN invasion was invariably deﬁned as  1 metastatic
LNs. Positive soft tissue surgical margin (PSTSM) was deﬁned asnical Genitourinary Cancer Month 2015the presence of tumor at inked areas of soft tissue on the RC
specimen.
Clinical and radiological follow-up consisted of a baseline visit at
3 to 4 months after surgery. Subsequently, the minimum follow-up
consisted of at least 2 annual visits. Examinations included radio-
logical imaging with computed tomography in all patients. In
addition to physical examination with laboratory testing, intrave-
nous pyelography, cystoscopy, urine cytology, urethral washings,
and bone scan were carried out if indicated.
Statistical Analyses
Descriptive statistics of categorical variables focused on fre-
quencies and proportions. Means, medians, and interquartile
ranges were reported for continuously coded variables. The
ManneWhitney test and c2 test were used to compare the sta-
tistical signiﬁcance of differences in medians and proportions,
respectively.
Our analyses consisted of different steps. First, KaplaneMeier
analyses were used to evaluate the effect of PBT on the recurrence,
OM, and CSM rates in the overall population and after stratiﬁca-
tion according to the timing of PBT. Second, multivariable Cox
regression analyses were used to test the relationship between receipt
of transfusion and the risk of recurrence, CSM, and OM after
adjusting for age, sex, CCI, PSTSM, pathological stage, number of
positive nodes, number of removed nodes, adjuvant chemotherapy,
and anemia status.
All statistical analyses were performed using SPSS version 22.0
(IBM Corp, Armonk, NY), with a 2-sided signiﬁcance level set at
P < .05.
Results
Baseline Characteristics
Clinical and pathological characteristics of patients included in
the study are shown in Table 1. Overall, 580 patients (38.9%)
received BT. Of these, 322 individuals (21.6%) received intra-
operative BT, 161 individuals (10.8%) received intraoperative
and postoperative BT, 97 individuals (6.5%) received post-
operative BT. As expected, patients who received intraoperative
and postoperative BT had lower preoperative Hb values, were
more anemic, and lost more blood during surgery (all P < .001).
Moreover, patients who received BT had the higher rate of
LNs removed and of positive surgical margin (all P < .02).
Finally, no statistically signiﬁcant difference was detected in age,
BMI, CCI, pathological T stage, Grade (WHO 1973), carcinoma
in situ, number of positive nodes, or neoadjuvant or adjuvant
chemotherapy, according to the timing of BT administration
(all P > .1).
Survival Estimates
Mean (median) follow-up was 125.13 (110) months after sur-
gery. Overall, the 5- and 10-year CSM survival-free rates were 58%
and 48% (Figure 1A). After stratiﬁcation according to the timing of
BT administration (no transfusion vs. postoperative transfusion vs.
intraoperative transfusion vs. intraoperative and postoperative
transfusion), the 5- and 10-year CSM rates were 64% and 52%
versus 60% and 60% versus 49% and 42% versus 50% and 40%,
respectively (P < .001; Figure 1B). Moreover, patients who received
Table 1 Descriptive Statistics of 1490 Patients Treated With RC for BCa Between 1990 and 2013 Stratiﬁed According to
Administration of PBT
Variables
Overall
(n [ 1490; 100%)
Intraoperative BT
(n [ 322; 21.6%)
Intraoperative and
Postoperative BT
(n [ 161; 10.8%)
Postoperative BT
(n [ 97; 6.5%)
No Transfusion
(n [ 910; 61.1%) P
Age .8
Mean 67.1 67.0 68.0 66.5 67.0
Median (IQR) 68 (61-74) 68 (61-75) 68 (63-74) 68 (61-74) 68 (61-74)
Sex .5
Male 1245 (83.6%) 260 (80.7%) 130 (80.7%) 76 (78.4%) 779 (85.6%)
Female 245 (16.4%) 62 (19.3%) 31 (19.3%) 21 (21.6%) 131 (14.4%)
BMI .8
Mean 25.6 25.7 25.8 25.5 25.4
Median (IQR) 25.2 (23.4-27.8) 25.3 (23.2-27.5) 25.3 (23.5-28.0) 24.9 (23.9-28.0) 25.1 (22.7-28.4)
CCI .2
0 525 (35.2%) 99 (30.7%) 52 (32.3%) 41 (42.3%) 333 (36.6%)
1 549 (36.8%) 121 (37.6%) 76 (47.6%) 36 (37.1%) 316 (34.7%)
2 416 (28.0%) 102 (31.7%) 33 (20.5%) 20 (20.6%) 261 (28.7%)
Preoperative Hb, mg/dL
Mean 12.5 12.3 11.7 12.7 12.9 <.001
Median (IQR) 12.6 (11.1-13.9) 12.4 (11.0-13.8) 11.7 (10.4-12.9) 13.0 (11.4-14.0) 13.2 (11.7-14.3)
Anemic Status 768 (51.5%) 208 (64.6%) 108 (67.1%) 65 (67.0%) 387 (42.5%) <.001
Positive Nodes .2
Mean 2.4 2.6 2.8 3.3 2.2
Median (IQR) 0 (0-2) 0 (0-2) 0 (0-2) 0 (0-3.5) 0 (0-1)
Nodes Removed .003
Mean 18.3 18.5 18.0 22.1 17.9
Median (IQR) 17 (11-24) 16 (10-24) 16 (10-25) 22 (16.0-28.0) 16 (11-23)
Pathological Stage .3
pT0-pT2 650 (43.6%) 136 (42.2%) 65 (40.4%) 42 (43.3%) 407 (44.7%)
pT3 547 (36.7%) 121 (37.6%) 61 (37.9%) 36 (37.1%) 329 (36.2%)
pT4 293 (19.7%) 65 (20.2%) 35 (21.7%) 19 (19.6%) 174 (19.1%)
Grade .3
1-2 452 (30.3%) 93 (28.9%) 53 (32.9%) 31 (32.0%) 275 (30.2%)
3-4 1038 (69.7%) 229 (71.7%) 108 (67.1%) 66 (68.0%) 635 (69.8%)
Blood Loss, cc <.001
Mean 1494 1561 1779 985 1031
Median (IQR) 1200 (800-1800) 1400 (962-1900) 1500 (1000-2100) 800 (500-1400) 800 (600-1100)
CIS 307 (20.6%) 65 (20.2%) 33 (20.5%) 19 (19.6%) 190 (20.9%) .9
Surgical Margin 114 (7.7%) 31 (9.6%) 16 (9.9%) 9 (9.3%) 58 (6.4%) .02
Neoadjuvant CT 43 (2.9%) 11 (3.4%) 6 (3.7%) 3 (3.1%) 23 (2.5%) .1
Adjuvant CT 384 (25.8%) 92 (28.6%) 46 (28.6%) 28 (28.9%) 218 (24.0%) .3
Abbreviations: BCa ¼ bladder cancer; BMI ¼ body mass index; BT ¼ blood transfusion; CCI ¼ Charlson Comorbidity Index; CIS ¼ carcinoma in situ; CT ¼ chemotherapy; Hb ¼ hemoglobin;
IQR ¼ interquartile range; PBT ¼ perioperative blood transfusion; RC ¼ radical prostatectomy.
Marco Moschini et alintraoperative or intra- and postoperative transfusion had a signiﬁ-
cantly lower rate of 10-year OM-free rates, compared with patients
who received postoperative BT or patients who did not receive BT
(P < .001; Figure 1C). Similar results were found in an evaluation
of 10-year recurrence-free rates (P ¼ .02; Figure 1D). No differ-
ences were reported in disease recurrence, OM, and CSM rates
between intraoperative and intraoperative with postoperative BT
(all P > .3).Multivariable Cox Regression Analyses in the Overall
Population and Stratiﬁed According to Anemia Status
Table 2 shows multivariable Cox regression analyses for assess-
ment of the relationship between receipt of transfusion and the risk
of recurrence, CSM, and OM. Because of the absence of a signiﬁ-
cant difference between patients who received intraoperative BT
and patients who received intra- and postoperative BT, we com-
bined these 2 groups in multivariable Cox regression analyses.Clinical Genitourinary Cancer Month 2015 - 3
Figure 1 KaplaneMeier Analysis of Cancer-Speciﬁc Mortality (CSM)-Free Rates in (A) the Overall Population, (B) and CSM, (C) Overall
Mortality, and (D) Recurrence-Free Rates Stratiﬁed According Administration of Blood Transfusion (BT)
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4 - CliReceipt of postoperative BT was not associated with increased risk
of CSM, OM, or disease recurrence (all P > .2). However, receipt
of intraoperative BT was signiﬁcantly associated with CSM (hazard
ratio [HR], 1.60; 95% conﬁdence interval [CI], 1.20-2.26; P ¼ .02),
OM (HR, 1.45; 95% CI, 1.02-2.08; P ¼ .03), and disease recur-
rence (HR, 1.24; 95% CI, 1.03-1.65; P ¼ .04; Table 2).
Discussion
Perioperative BT has been proposed as a possible predictor of
poor survival expectance in several malignancies.12-17 We tested the
hypothesis that intraoperative BT at our center increased a negative
effect on survival of patients affected by BCa treated with RC. Our
ﬁndings conﬁrmed that intraoperative but not postoperative BT is
associated with a signiﬁcant increase of CSM, OM, and disease
recurrence. These results were conﬁrmed even after accounting
for demographic characteristics and pathological confounders and
mainly after accounting for preoperative anemia status andnical Genitourinary Cancer Month 2015comorbidities, which were advocated as 2 factors that are potentially
implicated. Interestingly, no differences were found in terms of
survival between postoperative BT and patients who did not receive
a BT.
In this context, our data conﬁrm the ﬁndings of Abel et al21 who
demonstrated in a contemporary population of patients treated with
RC between 2002 and 2012, that intraoperative BT has a detri-
mental effect on survival. Subsequently, the authors conﬁrmed these
results with a validation cohort of 1770 patients treated with RC
between 1980 and 2005. In this cohort, the 5- and 10-year CSM-
free rates for patients who did not receive BT and for patients who
underwent postoperative BT were 76% and 69% versus 73% and
67%. However, the 5- and 10-year CSM-free rates for individuals
who underwent intraoperative BT and for individuals who under-
went intraoperative and postoperative BT were 60% and 55%
versus 59% and 51%, respectively. These ﬁndings were comparable
in our series. Speciﬁcally, our 5- and 10-year CSM-free survival rates
Table 2 Multivariate Cox Regression Analyses Predicting the Risk of Recurrence, CSM and OM in Patients Treated With Radical
Cystectomy
Variable
Multivariate Recurrence Multivariate CSM Multivariate OM
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age, Years 1.00 (0.98-1.02) .8 1.00 (0.99-1.02) .5 1.01 (0.99-1.03) .2
Sex (Ref: Female) 1.02 (0.64-1.62) .9 1.23 (0.80-.1.89) .2 1.25 (0.84-1.86) .2
CCI
0 Ref Ref Ref Ref Ref Ref
1 1.80 (1.10-2.95) .02 1.52 (0.93-2.48) .1 1.58 (1.00-2.50) .05
2 1.79 (1.07-3.01) .03 1.60 (0.96-2.66) .03 2.04 (1.28-3.24) .003
PST SM 1.81 (1.02-3.22) .03 1.31 (0.86-2.45) .1 1.25 (0.74-2.11) .4
Pathological Stage
pT0-T2 Ref Ref Ref Ref Ref Ref
pT3 2.46 (1.51-4.01) <.001 3.36 (2.04-5.53) <.001 2.63 (1.75-3.96) <.001
pT4 2.77 (1.48-5.19) <.001 4.47 (2.46-8.11) <.001 3.73 (2.24-6.23) <.001
Number of Positive Nodes 1.06 (1.04-1.09) <.001 1.08 (1.05-1.10) <.001 1.07 (1.04-1.10) <.001
Number of Nodes Removed 0.98 (0.96-1.94) .03 0.97 (0.95-0.99) .002 0.97 (0.96-0.99) .001
Adjuvant Chemotherapy 1.59 (1.08-2.33) .02 0.86 (0.58-1.29) .5 0.76 (0.52-1.11) .1
Anemia Status 0.79 (0.55-1.13) .08 0.62 (0.44-0.88) .01 0.67 (0.49-0.92) .01
Receipt of BT
No BT Ref Ref Ref Ref Ref Ref
Postoperative BT 1.50 (0.78-2.89) .5 1.60 (0.81-3.17) .2 1.36 (0.72-2.60) .4
Intraoperative BT 1.24 (1.03-1.65) .04 1.60 (1.20-2.26) .02 1.45 (1.02-2.08) .03
Abbreviations: BT ¼ blood transfusion; CCI ¼ Charlson comorbidity Index; CSM ¼ cancer-speciﬁc mortality; HR ¼ hazard ratio; OM ¼ overall mortality; PSTSM ¼ positive soft tissue surgical margin;
Ref ¼ reference.
Marco Moschini et alwere 64% and 52% versus 60% and 60% for patients without BT
and for patients who underwent postoperative BT. Although 5- and
10-year CSM-free survival rates for men who received intraoperative
BT and who underwent intraoperative and postoperative BT, were
49% and 42% versus 50% and 40%, respectively. Others previous
investigators assessed the association between BT and oncologic
outcomes in the RC population. In this context, Morgan et al9 in
their study assessed the effect of BT and survival in a population
with a limited follow-up (median, 25 months) and did not account
for preoperative Hb levels. Kluth et al11 failed to report an associ-
ation between BT and survival in a numerous multicentric cohort.
Gierth et al10 described in a monocentric series of 350 patients with
RC a detrimental effect of BT on survival after accounting for
anemia status as a confounder in a multivariable model. Finally,
Linder et al8 presented a report on the largest cohort available in
the literature on 2060 RC patients, with a median follow-up of
10.9 years. They demonstrated that perioperative BT is associated
with increased risk of postoperative tumor recurrence, CSM, and
OM after RC even after accounting for all available preoperative
confounders. Of note, these studies were limited by the absence
of stratiﬁcation between intraoperative and postoperative BT,8-11
and by short follow-up.9,10
From a biological standpoint, several theories could explain the
association between BT and the detrimental effect on survival after
surgery. First, the immunosuppressive effect of BT was previously
described in the literature as related to transfusion-related immune
modulation.18 Immune modulation is mediated by suppression of
cytotoxic cell and monocyte activity, release of immunosuppressiveprostaglandins, inhibition of interleukin-2 production, and increase
in suppressor of T-cell activity.24 Second, transfusion-induced
anergy due to the presentations of large amounts of antigens dur-
ing BT could also explain these results; this type of effect was used
therapeutically to reduce renal allograft rejection before immuno-
suppressant drugs become available. It was also described as a
transfusion-induced anergy due to the presentations of large
amounts of antigen during PBT.25 This type of effect is used
therapeutically to reduce renal allograft rejection when immuno-
suppressant drugs become available.26 However, at the moment no
consensus has been reached about the real effect of BT on survival
and further studies are needed to better understand the mechanisms
of this effect. More speciﬁcally, considering intraoperative BT,
further theories advocated consist of an increased spread of tumor
cells caused by surgical manipulation20 or an association between a
decreased host immunity caused by anesthetics and opioids that can
have a synergic effect with cancer manipulation.19
The importance of our study in relation to previous reports
consists of several aspects. First, our investigation represents the ﬁrst
conﬁrmation of the ﬁndings of Abel et al21 using a large European
single-institution cohort. This is fundamental considering the
clinical implications that can be applied to these patients. Second,
our report conﬁrms in a monocentric setting that physicians should
consider timing as a crucial parameter when BT is indicated.
Despite several strengths, our study is not devoid of limitations.
First and foremost we recognize that our study is limited by its
observational nature, and thus our results should be interpreted
within the limits of its retrospective design. For example, theClinical Genitourinary Cancer Month 2015 - 5
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6 - Cliadministration of BT was not standardized overall and was left to
the clinical judgement of each treating physician. However, we
partially addressed this limitation considering the monocentric sta-
tus of our report, and all the parameters considered by the physi-
cians in the decision for administration of BT were taken into
account in multivariable analyses. Moreover, no comparisons were
made considering autologous compared with allogeneic transfusion.
However, previous retrospective and prospective series in prostate16
or rectal27 cancers did not show any beneﬁt from autologous
transfusion compared with standard allogeneic transfusion.
Conclusion
We use a large single-institution series with long-term follow-up
to conﬁrm for the ﬁrst time that intraoperative, but not post-
operative BT, are related to a detrimental effect on survival in
patients affected by BCa who undergo RC. These results should be
taking into account by physicians to administer PBT according to
the correct timing.
Clinical Practice Points
 Transfusion has been related to poor survival after major sur-
geries in several cancers. Recently, timing of transfusion has been
advocated as crucial in determining this connection as a conse-
quence of their immunosuppressive effect and/or the related
increased intraoperative cancer manipulation.
 Our investigation demonstrated that intraoperative but not
postoperative transfusion are related to poor survival after RC in
BCa patients.
 These observations highlight the importance of timing in the
administration of transfusion in BCa patients. Physicians should
avoid transfusion intraoperatively.
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